Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
SANOFI INDIA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SANOFI INDIA Dec-23 |
ADCOCK INGRAM Jun-14 |
SANOFI INDIA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 8,278 | 314 | - | |
Low | Rs | 5,240 | 226 | - | |
Sales per share (Unadj.) | Rs | 1,238.0 | 93.4 | - | |
Earnings per share (Unadj.) | Rs | 261.8 | -23.5 | - | |
Cash flow per share (Unadj.) | Rs | 279.0 | -19.5 | - | |
Dividends per share (Unadj.) | Rs | 167.00 | 0 | - | |
Avg Dividend yield | % | 2.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 411.2 | 73.3 | - | |
Shares outstanding (eoy) | m | 23.03 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 5.5 | 2.9 | 188.7% | |
Avg P/E ratio | x | 25.8 | -11.5 | -224.8% | |
P/CF ratio (eoy) | x | 24.2 | -13.9 | -174.9% | |
Price / Book Value ratio | x | 16.4 | 3.7 | 445.9% | |
Dividend payout | % | 63.8 | 0 | - | |
Avg Mkt Cap | Rs m | 155,659 | 45,603 | 341.3% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 3,706 | 2,862 | 129.5% | |
Avg. sales/employee | Rs Th | 0 | 3,671.4 | - | |
Avg. wages/employee | Rs Th | 0 | 666.7 | - | |
Avg. net profit/employee | Rs Th | 0 | -925.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 28,511 | 15,761 | 180.9% | |
Other income | Rs m | 665 | 110 | 602.5% | |
Total revenues | Rs m | 29,176 | 15,872 | 183.8% | |
Gross profit | Rs m | 8,203 | -2,731 | -300.3% | |
Depreciation | Rs m | 396 | 680 | 58.2% | |
Interest | Rs m | 17 | 427 | 4.0% | |
Profit before tax | Rs m | 8,455 | -3,728 | -226.8% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,426 | 233 | 1,041.4% | |
Profit after tax | Rs m | 6,029 | -3,971 | -151.8% | |
Gross profit margin | % | 28.8 | -17.3 | -166.0% | |
Effective tax rate | % | 28.7 | -6.2 | -459.2% | |
Net profit margin | % | 21.1 | -25.2 | -83.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 31,314 | 11,544 | 271.3% | |
Current liabilities | Rs m | 25,347 | 6,495 | 390.3% | |
Net working cap to sales | % | 20.9 | 32.0 | 65.3% | |
Current ratio | x | 1.2 | 1.8 | 69.5% | |
Inventory Days | Days | 159 | 111 | 143.2% | |
Debtors Days | Days | 17 | 124 | 13.6% | |
Net fixed assets | Rs m | 15,714 | 6,729 | 233.5% | |
Share capital | Rs m | 230 | 73 | 314.3% | |
Net worth | Rs m | 9,469 | 12,371 | 76.5% | |
Long term debt | Rs m | 0 | 4,347 | 0.0% | |
Total assets | Rs m | 47,028 | 23,369 | 201.2% | |
Interest coverage | x | 498.4 | -7.7 | -6,445.1% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.7 | 89.9% | |
Return on assets | % | 12.9 | -15.2 | -84.8% | |
Return on equity | % | 63.7 | -32.1 | -198.3% | |
Return on capital | % | 89.5 | -19.8 | -451.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,304 | 1,345 | 171.3% | |
From Investments | Rs m | 375 | -413 | -90.8% | |
From Financial Activity | Rs m | -8,783 | 3,945 | -222.6% | |
Net Cashflow | Rs m | -6,104 | 4,878 | -125.1% |
Compare SANOFI INDIA With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare SANOFI INDIA With: LAURUS LABS FDC BH.IMMUN&BIO ISHITA DRUGS ORCHID PHARMA
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.